Source link : https://www.newshealth.biz/health-news/sglt2i-use-for-hf-rises-in-the-us-but-not-in-all-hospitals/
TOPLINE: The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in US patients hospitalized with heart failure (HF) and a left ventricular ejection fraction > 40% increased substantially within 2 years after evidence from a clinical trial demonstrated benefits of the treatment, according to a new study, but researchers found significant variation found among hospitals. METHODOLOGY: […]
Author : News Health
Publish date : 2024-11-19 12:27:59
Copyright for syndicated content belongs to the linked Source.